Sertificate of Registration GMP/LE/2004/002 Sertificate of Registration ISO 9001:2000 Sertificate of Registration ISO 9001:2000
Choose
your language:
English Russian
Choose the firm:
 Registrations
 Our partners
 Contact Us
 Search
 Price
For registered users
login
password
    
featured products
    Glucose 5%
    Cipro-Tech
    Iono-Tech
    Manni-Tech 10%
    Metronidazole 0.5%
    NaCl 0.9%
    Rheopolyglucinum
    Ringer
    Solutio Novocaini 0.25%
    Natrii citrati 4%
    Diprosalic Lotion 30 ml
    Freederm Shampoo Tar 150 ml
    Intron 18 miu 3ml 1 vial
    Triderm Cream 15 g
    Augmentin tab. 375mg N20
    Augmentin inj. 600mg N1
    Dermovate Oint 25g Tube
    Imigran Tab. 50mg N2
    Levitra 5mg 2 tab
    Mylogin Caps 250mg N10
    Mylogin Caps 250mg N20
    Oxybral Caps 30mg N20
    Septrin Paed Susp 100ml N1
    Valtrex tab. 500mg N10
    Vitamax Caps N5
    Zantac Tab. 150mg N20
    Zeffix Tab 100mgx28
    Zinacef Inj 750mg N1
    Zofran Tab 4mg N10
    Zyban 150 mg tabs. X 60
    Wellbutrin SR 150mg 60 tab
    Astmopent Aer 400Ds 0.75mg
    Salbutamol inh
information about product

POLYGLUCINUM-PHARMATECH
(Intravenous solution for injection)

The trading (patented) name of preparation - POLYGLUCINUM-PHARMATECH
The international name
DEXTRAN
ATC-Code B05AA05


STRUCTURE AND THE FORM OF RELEASE
1 litre of solution contains
Dextran 60000+10000..... 60 g
Sodium Chloride ................... 9g
Other ingredients: water for injection
200, 250, 400, 500 ml of solution in plastic PVC containers.


PHARMACOLOGICAL EFFEC
Polyglucinum is considered as a substitute for plasama, antshock preparation with hemodinamic effect. Thanks to comparatively big relative molecular mass, such as blood albumin, polyglucinum penetrates slowly through blood vessels and when administred into blood channel it ciruculates there longer resulting in higher blood pressure during blood loss holdiling it for a long period of time in high level.

INDICATIONS FOR ADMINISTRATION
Polyclucinum is administered for prophylactic and medical purposes during traumatic and operating shocks, critical blood pressure, during shocks in result of intoxication, sepsis etc.

DOSAGE
Administrated intravenously, but during critical blood losses intra-arterial. During developing shocks the administration of polyglucinum is intravenous in drop infusion starting from 400 ml to 1200 ml with direct influence (when necessary about 2000 ml). For the treatment of burn shocks about 20000-3000 ml is injected in the first 24 hours and in the following 24 hours about 1500 ml. When administered to children for the first time in 24 hour period up to 40-50ml of preparation is given for 1 kg of body weight and during the following days - 30 ml/kg.

SIDE-EFFECTS
During the administration of polyglucinum allergic reactions are possible (itching, (o)edema), rapid pulse, lowering of arterial pressure.

CONTRAINDICATION
Polyglucinum is contradicted for administration during cranial/skull traumas with high intracranial pressure (danger of high arterial pressure), brain hemorrhage and in cases when it is unacceptable to administer big quantities of fluid; water, kidney disease (with anuria), heart disorders, disposition to sharply expressed allergic reaction.

PREGNANCY AND LACTATION
Contraindications are not revealed about the administration of the preparation during pregnancy and lactation.

SPECIAL INDICATIONS
During the intravenous administration of polyglucinum when the following symptoms are observed like complaints of restraint in the area of the chest; heavy breathing; pain in the area of loins, as well as fever, cyanosis, disturbance of blood circulation and breathing, transfusion is stopped and intravenous injection of 10 ml of Calcium Chloride 10% solution , 20 ml of Glucose 40% Solution is made, cardiovascular and antihistamine preparations are used.

STORAGE CONDITIONS AND SHELF LIFE
The preparation should be stored at temperature +10 - +25o. Expiry date - 3 years.

  Copyright © 2006 PharmaTech